12-13-06-Final Draft PI
Product Information
PegIntron™
(Peginterferon alfa-2b)
Powder For Injection

Alpha interferons, including PegIntron™, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping PegIntron™ therapy. See WARNINGS, ADVERSE REACTIONS.

Use with Ribavirin. Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen. (See REBETOL package insert for additional information and other warnings.)

DESCRIPTION
PegIntron™, peginterferon alfa-2b, Powder for Injection is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PegIntron™ molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately $0.7 \times 10^8$ IU/mg protein.

Interferon alfa-2b, is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the
bacterial fermentation of a strain of *Escherichia coli* bearing a genetically engineered plasmid containing an interferon gene from human leukocytes.

**PegIntron™ is supplied in both vials and the Redipen® for subcutaneous use.**

**Vials**
Each vial contains either 74 mcg, 118.4 mcg, 177.6 mcg, or 222 mcg of PegIntron™ as a white to off-white tablet-like solid, that is whole/in pieces or as a loose powder, and 1.11 mg dibasic sodium phosphate anhydrous, 1.11 mg monobasic sodium phosphate dihydrate, 59.2 mg sucrose, and 0.074 mg polysorbate 80. Following reconstitution with 0.7 mL of the supplied Sterile Water for Injection, USP, each vial contains PegIntron™ at strengths of either 50 mcg per 0.5 mL, 80 mcg per 0.5 mL, 120 mcg per 0.5 mL, or 150 mcg per 0.5 mL.

**Redipen®**
Redipen® is a dual-chamber glass cartridge containing lyophilized PegIntron™ as a white to off-white tablet or powder that is whole or in pieces in the sterile active chamber and a second chamber containing Sterile Water for Injection, USP. Each PegIntron™ Redipen® contains either 67.5 mcg, 108 mcg, 162 mcg, or 202.5 mcg of PegIntron™, and 1.013 mg dibasic sodium phosphate anhydrous, 1.013 mg monobasic sodium phosphate dihydrate, 54 mg sucrose, and 0.0675 mg polysorbate 80. Each cartridge is reconstituted to allow for the administration of up to 0.5 mL of solution. Following reconstitution, each Redipen® contains PegIntron™ at strengths of either 50 mcg per 0.5 mL, 80 mcg per 0.5 mL, 120 mcg per 0.5 mL, or 150 mcg per 0.5mL for a single use. Because a small volume of reconstituted solution is lost during preparation of PegIntron™, each Redipen® contains an excess amount of PegIntron™ powder and diluent to ensure delivery of the labeled dose.

**CLINICAL PHARMACOLOGY**
**General:** The biological activity of PegIntron™ is derived from its interferon alfa-2b moiety. Interferons exert their cellular activities by binding to specific membrane receptors on the cell surface and initiate a complex sequence of intracellular events.
These include the induction of certain enzymes, suppression of cell proliferation, immunomodulating activities such as enhancement of the phagocytic activity of macrophages and augmentation of the specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells. Interferon alfa upregulates the Th1 T-helper cell subset in \textit{in vitro} studies. The clinical relevance of these findings is not known.

**Pharmacodynamics:** PegIntron™ raises concentrations of effector proteins such as serum neopterin and 2’5’ oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts. The correlation between the \textit{in vitro} and \textit{in vivo} pharmacologic and pharmacodynamic and clinical effects is unknown.

**Pharmacokinetics:** Following a single subcutaneous (SC) dose of PegIntron™, the mean absorption half-life (t $\frac{1}{2} k_a$) was 4.6 hours. Maximal serum concentrations (C$_{\text{max}}$) occur between 15-44 hours post-dose, and are sustained for up to 48-72 hours. The C$_{\text{max}}$ and AUC measurements of PegIntron™ increase in a dose-related manner. After multiple dosing, there is an increase in bioavailability of PegIntron™. Week 48 mean trough concentrations (320 pg/mL; range 0, 2960) are approximately 3-fold higher than Week 4 mean trough concentrations (94 pg/mL; range 0, 416). The mean PegIntron™ elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection. The apparent clearance of PegIntron™ is estimated to be approximately 22.0 mL/hr·kg. Renal elimination accounts for 30% of the clearance.

Pegylation of interferon alfa-2b produces a product (PegIntron™) whose clearance is lower than that of non-pegylated interferon alfa-2b. When compared to INTRON A, PegIntron™ (1 mcg/kg) has approximately a sevenfold lower mean apparent clearance and a fivefold greater mean half-life permitting a reduced dosing frequency. At effective therapeutic doses, PegIntron™ has approximately tenfold greater C$_{\text{max}}$ and 50-fold greater AUC than interferon alfa-2b.

**Special Populations**

**Renal Dysfunction**
Following multiple dosing of PegIntron™ (1 mcg/kg SC given every week for four weeks) the clearance of PegIntron™ is reduced by a mean of 17% in patients with moderate renal impairment (creatinine clearance 30-49 mL/min) and by a mean of 44% in patients with severe renal impairment (creatinine clearance 10-29 mL/min) compared to subjects with normal renal function. Clearance was similar in patients with severe renal impairment not on dialysis and patients who are receiving hemodialysis. The dose of PegIntron™ for monotherapy should be reduced in patients with moderate or severe renal impairment (see DOSAGE AND ADMINISTRATION: DOSE REDUCTION). REBETOL should not be used in patients with creatinine clearance < 50 mL/min (see REBETOL Package Insert, WARNINGS).

**Gender**

During the 48-week treatment period with PegIntron™, no differences in the pharmacokinetic profiles were observed between male and female patients with chronic hepatitis C infection.

**Geriatric Patients**

The pharmacokinetics of geriatric subjects (> 65 years of age) treated with a single subcutaneous dose of 1 mcg/kg of PegIntron™ were similar in C<sub>max</sub>, AUC, clearance, or elimination half-life as compared to younger subjects (28 to 44 years of age).

**Effect of Food on Absorption of Ribavirin**

Both AUC<sub>tf</sub> and C<sub>max</sub> increased by 70% when REBETOL Capsules were administered with a high-fat meal (841 kcal, 53.8 g fat, 31.6 g protein, and 57.4 g carbohydrate) in a single-dose pharmacokinetic study (see DOSAGE AND ADMINISTRATION).

**Drug Interactions**

**Drugs Metabolized by Cytochrome P-450**

The pharmacokinetics of representative drugs metabolized by CYP1A2 (caffeine), CYP2C8/9 (tolbutamide), CYP2D6 (dextromethorphan), CYP3A4 (midazolam), and
N-acetyltransferase (dapsone) were studied in 22 patients with chronic hepatitis C who received PegIntron™ (1.5mcg/kg) once weekly for 4 weeks. PegIntron™ treatment resulted in a 28% (mean) increase in a measure of CYP2C8/9 activity. PegIntron™ treatment also resulted in a 66% (mean) increase in a measure of CYP2D6 activity; however, the effect was variable as 13 patients had an increase, 5 patients had a decrease, and 4 patients had no significant change (see PRECAUTIONS: Drug Interactions).

No significant effect was observed on the pharmacokinetics of representative drugs metabolized by CYP1A2, CYP3A4, or N-acetyltransferase. The effects of PegIntron™ on CYP2C19 activity were not assessed.

**Methadone**

The pharmacokinetics of concomitant administration of methadone and PegIntron™ were evaluated in 18 PegIntron™ naïve chronic hepatitis C patients receiving 1.5 mcg/kg/week PegIntron™ SC weekly. All patients were on stable methadone maintenance therapy receiving ≥40 mg/day prior to initiating PegIntron™. Mean methadone AUC was approximately 16% higher after 4 weeks of PegIntron™ treatment as compared to baseline. In 2 patients, methadone AUC was approximately double after 4 weeks of PegIntron™ treatment as compared to baseline (see PRECAUTIONS: Drug Interactions).

**Use with Ribavirin:**

Ribavirin has been shown *in vitro* to inhibit phosphorylation of zidovudine, lamivudine and stavudine. However, in a study with another pegylated interferon in combination with ribavirin, no pharmacokinetic (eg, plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (eg, loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were co-administered as part of a multi-drug regimen to HIV/HCV co-infected patients. Exposure to didanosine or its active metabolite (dideoxyadenosine 5'—
triphosphate) is increased when didanosine is co-administered with ribavirin, which could cause or worsen clinical toxicities (see PRECAUTIONS: Drug Interactions).

CLINICAL STUDIES

PegIntron™ Monotherapy-Study 1

A randomized study compared treatment with PegIntron™ (0.5, 1, or 1.5 mcg/kg once weekly SC) to treatment with INTRON A (3 million units three times weekly SC) in 1219 adults with chronic hepatitis from HCV infection. The patients were not previously treated with interferon alfa, had compensated liver disease, detectable HCV RNA, elevated ALT, and liver histopathology consistent with chronic hepatitis. Patients were treated for 48 weeks and were followed for 24 weeks posttreatment.

Seventy percent of all patients were infected with HCV genotype 1, and 74 percent of all patients had high baseline levels of HCV RNA (more than 2 million copies per mL of serum), two factors known to predict poor response to treatment.

Response to treatment was defined as undetectable HCV RNA and normalization of ALT at 24 weeks posttreatment. The response rates to the 1 and 1.5 mcg/kg PegIntron™ doses were similar (approximately 24%) to each other and were both higher than the response rate to INTRON A (12%). (See Table 1.)
Table 1. Rates of Response to Treatment-Study 1

<table>
<thead>
<tr>
<th></th>
<th>A PegIntron™ 0.5 mcg/kg (N=315)</th>
<th>B PegIntron™ 1 mcg/kg (N=298)</th>
<th>C INTRON A 3 MIU TIW (N=307)</th>
<th>B - C (95% CI) Difference between PegIntron™ 1 mcg/kg and INTRON A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment Response</td>
<td>17%</td>
<td>24%</td>
<td>12%</td>
<td>11 (5, 18)</td>
</tr>
<tr>
<td>(Combined Virologic Response and ALT Normalization)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virologic Response</td>
<td>18%</td>
<td>25%</td>
<td>12%</td>
<td>12 (6,19)</td>
</tr>
<tr>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT Normalization</td>
<td>24%</td>
<td>29%</td>
<td>18%</td>
<td>11 (5,18)</td>
</tr>
</tbody>
</table>

Serum HCV is measured by a research-based quantitative polymerase chain reaction assay by a central laboratory.

Patients with both viral genotype 1 and high serum levels of HCV RNA at baseline were less likely to respond to treatment with PegIntron™. Among patients with the two unfavorable prognostic variables, 8% (12/157) responded to PegIntron™ treatment and 2% (4/169) responded to INTRON A. Doses of PegIntron™ higher than the recommended dose did not result in higher response rates in these patients.

Patients receiving PegIntron™ with viral genotype 1 had a response rate of 14% (28/199) while patients with other viral genotypes had a 45% (43/96) response rate.

Ninety-six percent of the responders in the PegIntron™ groups and 100% of responders in the INTRON A group first cleared their viral RNA by week-24 of treatment (see DOSAGE AND ADMINISTRATION).

The treatment response rates were similar in men and women. Response rates were lower in African American and Hispanic patients and higher in Asians compared to Caucasians. Although African Americans had a higher proportion of poor prognostic factors compared to Caucasians, the number of non-Caucasians studied (9% of the total) was insufficient to allow meaningful conclusions about differences in response rates after adjusting for prognostic factors.
Liver biopsies were obtained before and after treatment in 60% of patients. A modest reduction in inflammation compared to baseline that was similar in all four treatment groups was observed.

**PegIntron™/REBETOL Combination Therapy-Study 2**

A randomized study compared treatment with two PegIntron™/REBETOL regimens [PegIntron™ 1.5 mcg/kg SC once weekly (QW)/REBETOL 800 mg PO daily (in divided doses); PegIntron™ 1.5 mcg/kg SC QW for 4 weeks then 0.5 mcg/kg SC QW for 44 weeks/REBETOL 1000/1200 mg PO daily (in divided doses)] with INTRON A [3 MIU SC thrice weekly (TIW)/REBETOL 1000/1200 mg PO daily (in divided doses)] in 1530 adults with chronic hepatitis C. Interferon naïve patients were treated for 48 weeks and followed for 24 weeks posttreatment. Eligible patients had compensated liver disease, detectable HCV RNA, elevated ALT, and liver histopathology consistent with chronic hepatitis.

Response to treatment was defined as undetectable HCV RNA at 24 weeks posttreatment. The response rate to the PegIntron™ 1.5 mcg/kg plus ribavirin 800 mg dose was higher than the response rate to Intron A/REBETOL (see Table 2). The response rate to PegIntron™ 1.5→0.5 mcg/kg/REBETOL was essentially the same as the response to INTRON A/REBETOL (data not shown).

**Table 2. Rates of Response to Treatment - Study 2**

<table>
<thead>
<tr>
<th></th>
<th>PegIntron™ 1.5 mcg/kg QW REBETOL 800 mg QD</th>
<th>INTRON A 3 MIU TIW REBETOL 1000/1200 mg QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall response 1,2</td>
<td>52% (264/511)</td>
<td>46% (231/505)</td>
</tr>
<tr>
<td>Genotype 1</td>
<td>41% (141/348)</td>
<td>33% (112/343)</td>
</tr>
<tr>
<td>Genotype 2-6</td>
<td>75% (123/163)</td>
<td>73% (119/162)</td>
</tr>
</tbody>
</table>

1Serum HCV RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory.

2Difference in overall treatment response (PegIntron™/REBETOL vs. INTRON A/REBETOL) is 6% with 95% confidence interval of (0.18, 11.63) adjusted for viral genotype and presence of cirrhosis at baseline.
Patients with viral genotype 1, regardless of viral load, had a lower response rate to PegIntron™ (1.5 mcg/kg)/REBETOL compared to patients with other viral genotypes. Patients with both poor prognostic factors (genotype 1 and high viral load) had a response rate of 30% (78/256) compared to a response rate of 29% (71/247) with INTRON A/REBETOL.

Patients with lower body weight tended to have higher adverse event rates (see ADVERSE REACTIONS) and higher response rates than patients with higher body weights. Differences in response rates between treatment arms did not substantially vary with body weight.

Treatment response rates with PegIntron™/REBETOL were 49% in men and 56% in women. Response rates were lower in African American and Hispanic patients and higher in Asians compared to Caucasians. Although African Americans had a higher proportion of poor prognostic factors compared to Caucasians, the number of non-Caucasians studied (11% of the total) was insufficient to allow meaningful conclusions about differences in response rates after adjusting for prognostic factors.

Liver biopsies were obtained before and after treatment in 68% of patients. Compared to baseline approximately 2/3 of patients in all treatment groups were observed to have a modest reduction in inflammation.

INDICATIONS AND USAGE

PegIntron™, peginterferon alfa-2b, is indicated for use alone or in combination with REBETOL (ribavirin, USP) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age.

CONTRAINDICATIONS

PegIntron™ is contraindicated in patients with:

- hypersensitivity to PegIntron™ or any other component of the product
- autoimmune hepatitis
10

- hepatic decompensation (Child-Pugh score >6 [class B and C]) in cirrhotic CHC patients before or during treatment.

PegIntron™/REBETOL combination therapy is additionally contraindicated in:

- patients with hypersensitivity to ribavirin or any other component of the product
- women who are pregnant
- men whose female partners are pregnant
- patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia)
- patients with creatinine clearance < 50 mL/min

WARNINGS

Patients should be monitored for the following serious conditions, some of which may become life threatening. Patients with persistently severe or worsening signs or symptoms should be withdrawn from therapy.

Neuropsychiatric events

Life-threatening or fatal neuropsychiatric events, including suicide, suicidal and homicidal ideation, depression, relapse of drug addiction/overdose, and aggressive behavior have occurred in patients with and without a previous psychiatric disorder during PegIntron™ treatment and follow-up. Psychoses, hallucinations, bipolar disorders, and mania have been observed in patients treated with alpha interferons. PegIntron™ should be used with extreme caution in patients with a history of psychiatric disorders. Patients should be advised to report immediately any symptoms of depression and/or suicidal ideation to their prescribing physicians. Physicians should monitor all patients for evidence of depression and other psychiatric symptoms. If patients develop psychiatric problems, including clinical depression, it is recommended that the patients be carefully monitored during treatment and in the 6 month-follow-up period. If psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended that treatment with PegIntron™ be discontinued, and the patient followed, with psychiatric intervention as appropriate. In severe cases, PegIntron™
should be stopped immediately and psychiatric intervention instituted. (See DOSAGE AND ADMINISTRATION: Dose Reduction.) Cases of encephalopathy have been observed in some patients, usually elderly, treated with higher doses of PegIntron™.

**Bone marrow toxicity**

PegIntron™ suppresses bone marrow function, sometimes resulting in severe cytopenias. PegIntron™ should be discontinued in patients who develop severe decreases in neutrophil or platelet counts (see DOSAGE AND ADMINISTRATION: Dose Reduction). Ribavirin may potentiate the neutropenia induced by interferon alpha. Very rarely alpha interferons may be associated with aplastic anemia.

**Hepatic Failure**

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PegIntron™. Cirrhotic CHC patients co-infected with HIV receiving highly active antiretroviral therapy (HAART) and alpha interferons with or without ribavirin appear to be at increased risk for the development of hepatic decompensation compared to patients not receiving HAART. During treatment, patients’ clinical status and hepatic function should be closely monitored, and PegIntron™ treatment should be immediately discontinued if decompensation (Child-Pugh score >6) is observed (see CONTRAINDICATIONS).

**Endocrine disorders**

PegIntron™ causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia has been observed in patients treated with PegIntron™. Diabetes mellitus has been observed in patients treated with alpha interferons. Patients with these conditions who cannot be effectively treated by medication should not begin PegIntron™ therapy. Patients who develop these conditions during treatment and cannot be controlled with medication should not continue PegIntron™ therapy.
Cardiovascular events

Cardiovascular events, which include hypotension, arrhythmia, tachycardia, cardiomyopathy, angina pectoris, and myocardial infarction, have been observed in patients treated with PegIntron™. PegIntron™ should be used cautiously in patients with cardiovascular disease. Patients with a history of myocardial infarction and arrhythmic disorder who require PegIntron™ therapy should be closely monitored (see Laboratory Tests). Patients with a history of significant or unstable cardiac disease should not be treated with PegIntron™/REBETOL combination therapy. (See REBETOL package insert.)

Cerebrovascular disorders

Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with Interferon alfa-based therapies, including PegIntron™. Events occurred in patients with few or no reported risk factors for stroke, including patients less than 45 years of age. Because these are spontaneous reports, estimates of frequency cannot be made and a causal relationship between Interferon alfa-based therapies and these events is difficult to establish.

Pulmonary disorders

Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, and sarcoidosis, some resulting in respiratory failure and/or patient deaths, may be induced or aggravated by PegIntron™ or alpha interferon therapy. Recurrence of respiratory failure has been observed with interferon rechallenge. PegIntron™ combination treatment should be suspended in patients who develop pulmonary infiltrates or pulmonary function impairment. Patients who resume interferon treatment should be closely monitored.
Colitis
Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment. Abdominal pain, bloody diarrhea, and fever are the typical manifestations. PegIntron™ treatment should be discontinued immediately in patients who develop these symptoms and signs. The colitis usually resolves within 1-3 weeks of discontinuation of alpha interferons.

Pancreatitis
Fatal and nonfatal pancreatitis have been observed in patients treated with alpha interferon. PegIntron™ therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.

Autoimmune disorders
Development or exacerbation of autoimmune disorders (eg, thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, psoriasis) have been observed in patients receiving PegIntron™. PegIntron™ should be used with caution in patients with autoimmune disorders.

Ophthalmologic disorders
Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, and papilledema may be induced or aggravated by treatment with peginterferon alfa-2b or other alpha interferons. All patients should receive an eye examination at baseline. Patients with preexisting ophthalmologic disorders (eg, diabetic or hypertensive retinopathy) should receive periodic ophthalmologic exams during interferon alpha treatment. Any patient who develops ocular symptoms should receive a prompt and complete eye examination. Peginterferon alfa-2b treatment should be discontinued in patients who develop new or worsening ophthalmologic disorders.
Hypersensitivity
Serious, acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) and cutaneous eruptions (Stevens Johnson syndrome, toxic epidermal necrolysis) have been rarely observed during alpha interferon therapy. If such a reaction develops during treatment with PegInteron™, discontinue treatment and institute appropriate medical therapy immediately. Transient rashes do not necessitate interruption of treatment.

Use with Ribavirin—(see also REBETOL Package Insert)
REBETOL may cause birth defects and/or death of the unborn child. REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Patients should use at least two forms of contraception and have monthly pregnancy tests (see BOXED WARNING, CONTRAINDICATIONS, and PRECAUTIONS: Information for Patients and REBETOL package insert).

Anemia
Ribavirin caused hemolytic anemia in 10% of PegInteron™/REBETOL-treated patients within 1-4 weeks of initiation of therapy. Complete blood counts should be obtained pretreatment and at week 2 and week 4 of therapy or more frequently if clinically indicated. Anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Decrease in dosage or discontinuation of REBETOL may be necessary. (See DOSAGE AND ADMINISTRATION: Dose Reduction.)

PRECAUTIONS
• PegInteron™ alone or in combination with REBETOL has not been studied in patients who have failed other alpha interferon treatments.
• The safety and efficacy of PegInteron™ alone or in combination with REBETOL for the treatment of hepatitis C in liver or other organ transplant recipients have not been studied. In a small (n=16) single-center, uncontrolled case experience, renal failure in renal allograft recipients receiving interferon alpha and ribavirin
combination therapy was more frequent than expected from the center’s previous experience with renal allograft recipients not receiving combination therapy. The relationship of the renal failure to renal allograft rejection is not clear.

- The safety and efficacy of PegIntron™/REBETOL for the treatment of patients with HCV co-infected with HIV or HBV have not been established.

**Triglycerides:**

Elevated triglyceride levels have been observed in patients treated with interferon alfa including PegIntron™ therapy. Hypertriglyceridemia may result in pancreatitis (see **WARNINGS: Pancreatitis**). Elevated triglyceride levels should be managed as clinically appropriate. Discontinuation of PegIntron™ therapy should be considered for patients with symptoms of potential pancreatitis, such as abdominal pain, nausea, or vomiting and persistently elevated triglycerides (eg, triglycerides >1000 mg/dL).

**Patients with Renal Insufficiency**

Increases in serum creatinine levels have been observed in patients with renal insufficiency receiving interferon alfa products, including PegIntron™. Patients with impaired renal function should be closely monitored for signs and symptoms of interferon toxicity, including increases in serum creatinine, and PegIntron™ dosing should be adjusted accordingly or discontinued (see **CLINICAL PHARMACOLOGY: Pharmacokinetics and DOSAGE AND ADMINISTRATION: Dose Reduction**). PegIntron™ monotherapy should be used with caution in patients with creatinine clearance < 50 mL/min; the potential risks should be weighed against the potential benefits in these patients. Combination therapy with REBETOL must not be used in patients with creatinine clearance < 50 mL/min (see **REBETOL Package Insert WARNINGS**).

**Information for Patients:** Patients receiving PegIntron™ alone or in combination with REBETOL should be directed in its appropriate use, informed of the benefits
and risks associated with treatment, and referred to the MEDICATION GUIDES for PegIntron™ and, if applicable, REBETOL (ribavirin, USP).

Patients must be informed that REBETOL may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during treatment with combination PegIntron™/REBETOL therapy and for 6 months posttherapy. Combination PegIntron™/REBETOL therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. It is recommended that patients undergo monthly pregnancy tests during therapy and for 6 months posttherapy (see CONTRAINDICATIONS and REBETOL package insert).

Patients should be informed that there are no data regarding whether PegIntron™ therapy will prevent transmission of HCV infection to others. Also, it is not known if treatment with PegIntron™ will cure hepatitis C or prevent cirrhosis, liver failure, or liver cancer that may be the result of infection with the hepatitis C virus.

Patients should be advised that laboratory evaluations are required before starting therapy and periodically thereafter (see Laboratory Tests). It is advised that patients be well hydrated, especially during the initial stages of treatment. "Flu-like" symptoms associated with administration of PegIntron™ may be minimized by bedtime administration of PegIntron™ or by use of antipyretics.

Patients should be advised to use a puncture-resistant container for the disposal of used syringes, needles, and the Redipen®. The full container should be disposed of in accordance with state and local laws. Patients should be thoroughly instructed in the importance of proper disposal. Patients should also be cautioned against reusing or sharing needles, syringes, or the Redipen®.

**Dental and periodontal disorders:**

Dental and periodontal disorders have been reported in patients receiving PegIntron™/REBETOL combination therapy. In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term
treatment with the combination of REBETOL and PegIntron™. Patients should
brush their teeth thoroughly twice daily and have regular dental examinations. If
vomiting occurs, patients should be advised to rinse out their mouth thoroughly
afterwards.

**Laboratory Tests:** PegIntron™ alone or in combination with ribavirin may cause
severe decreases in neutrophil and platelet counts, and hematologic, endocrine
(eg, TSH) and hepatic abnormalities. Transient elevations in ALT (2- to 5-fold above
baseline) were observed in 10% of patients treated with PegIntron™, and was not
associated with deterioration of other liver functions. Triglyceride levels are
frequently elevated in patients receiving alpha interferon therapy including
PegIntron™ and should be periodically monitored.

Patients on PegIntron™ or PegIntron™/REBETOL combination therapy
should have hematology and blood chemistry testing before the start of treatment
and then periodically thereafter. In the clinical trial CBC (including hemoglobin,
neutrophil, and platelet counts) and chemistries (including AST, ALT, bilirubin, and
uric acid) were measured during the treatment period at weeks 2, 4, 8, 12, and then
at 6-week intervals or more frequently if abnormalities developed. TSH levels were
measured every 12 weeks during the treatment period. HCV RNA should be
measured at 6 months of treatment. PegIntron™ or PegIntron™/REBETOL
combination therapy should be discontinued in patients with persistent high viral
levels.

Patients who have pre-existing cardiac abnormalities should have
electrocardiograms administered before treatment with PegIntron™/REBETOL.

**Drug Interactions**

Caution should be used when administering PegIntron™ with medications
metabolized by CYP2C8/9 (eg, warfarin and phenytoin) or CYP2D6 (eg, flecainide)
(see CLINICAL PHARMACOLOGY; Drug Interactions).

**Methadone**
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PegIntron™ once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC; in 2 out of 18 patients, methadone AUC doubled (see CLINICAL PHARMACOLOGY: Drug Interactions). The clinical significance of this finding is unknown; however, patients should be monitored for the signs and symptoms of increased narcotic effect.

Use with Ribavirin:

Nucleoside Analogues

Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon alfa and ribavirin. Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset. Patients receiving interferon with ribavirin and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anemia. Discontinuation of NRTIs should be considered as medically appropriate (see Individual NRTI Product Information). Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eg, Child-Pugh > 6).

Stavudine, Lamivudine, and Zidovudine: In vitro studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as stavudine, lamivudine, and zidovudine. In a study with another pegylated interferon alfa, no evidence of a pharmacokinetic or pharmacodynamic (eg, loss of HIV/HCV virologic suppression) interaction was seen when ribavirin was co-administered with zidovudine, lamivudine, or stavudine in HIV/HCV co-infected patients (see CLINICAL PHARMACOLOGY: Drug Interactions).

Although there was no evidence of loss of HIV/HCV virologic suppression when ribavirin was co-administered with zidovudine, HIV/HCV co-infected patients who were administered zidovudine in combination with pegylated interferon alfa and
ribavirin developed severe neutropenia (ANC <500) and severe anemia (hemoglobin <8 g/dL) more frequently than similar patients not receiving zidovudine.

**Didanosine**: Co-administration of REBETOL Capsules or Oral Solution and didanosine is not recommended. Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactactemia/lactic acidosis have been reported in clinical trials (see **CLINICAL PHARMACOLOGY: Drug Interactions**).

**Carcinogenesis, Mutagenesis, and Impairment of Fertility**

**Carcinogenesis and Mutagenesis**: PegIntron™ has not been tested for its carcinogenic potential. Neither PegIntron™, nor its components interferon or methoxypolyethylene glycol caused damage to DNA when tested in the standard battery of mutagenesis assays, in the presence and absence of metabolic activation.

**Use with Ribavirin**: Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen. See REBETOL package insert for additional warnings relevant to PegIntron™ therapy in combination with ribavirin.

**Impairment of Fertility**: PegIntron™ may impair human fertility. Irregular menstrual cycles were observed in female cynomolgus monkeys given subcutaneous injections of 4239 mcg/m² PegIntron™ alone every other day for one month (approximately 345 times the recommended weekly human dose based upon body surface area). These effects included transiently decreased serum levels of estradiol and progesterone, suggestive of anovulation. Normal menstrual cycles and serum hormone levels resumed in these animals 2 to 3 months following cessation of PegIntron™ treatment. Every other day dosing with 262 mcg/m² (approximately 21 times the weekly human dose) had no effects on cycle duration or reproductive hormone status. The effects of PegIntron™ on male fertility have not been studied.

**Pregnancy Category C**: PegIntron™ monotherapy: Non-pegylated Interferon alfa-2b, has been shown to have abortifacient effects in *Macaca mulatta* (rhesus monkeys) at 15 and 30 million IU/kg (estimated human equivalent of 5 and 10 million
IU/kg, based on body surface area adjustment for a 60 kg adult). PegIntron™ should be assumed to also have abortifacient potential. There are no adequate and well-controlled studies in pregnant women. PegIntron™ therapy is to be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Therefore, PegIntron™ is recommended for use in fertile women only when they are using effective contraception during the treatment period.

**Pregnancy Category X: Use with Ribavirin**

Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. REBETOL therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. See CONTRAINDICATIONS and the REBETOL Package Insert.

Ribavirin Pregnancy Registry: A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

**Nursing Mothers:** It is not known whether the components of PegIntron™ and/or REBETOL are excreted in human milk. Studies in mice have shown that mouse interferons are excreted in breast milk. Because of the potential for adverse reactions from the drug in nursing infants, a decision must be made whether to discontinue nursing or discontinue the PegIntron™ and REBETOL treatment, taking into account the importance of the therapy to the mother.

**Pediatric:** Safety and effectiveness in pediatric patients below the age of 18 years have not been established.

**Geriatric:** In general, younger patients tend to respond better than older patients to interferon-based therapies. Clinical studies of PegIntron™ alone or in combination with REBETOL did not include sufficient numbers of subjects aged 65 and over; however, to determine whether they respond differently than younger subjects.
Treatment with alpha interferons, including PegIntron™, is associated with neuropsychiatric, cardiac, pulmonary, GI, and systemic (flu-like) adverse effects. Because these adverse reactions may be more severe in the elderly, caution should be exercised in the use of PegIntron™ in this population. This drug is known to be substantially excreted by the kidney. Because elderly patients are more likely to have decreased renal function, the risk of toxic reactions to this drug may be greater in patients with impaired renal function (see CLINICAL PHARMACOLOGY: Special Populations: Renal Dysfunction). REBETOL should not be used in patients with creatinine clearance <50 mL/min. When using PegIntron™/REBETOL therapy, refer also to the REBETOL Package Insert.

ADVERSE REACTIONS

Nearly all study patients in clinical trials experienced one or more adverse events. In the PEG monotherapy trial the incidence of serious adverse events was similar (about 12%) in all treatment groups. In the PegIntron™/REBETOL combination trial, the incidence of serious adverse events was 17% in the PegIntron™/REBETOL groups compared to 14% in the INTRON A/REBETOL group.

In many but not all cases, adverse events resolved after dose reduction or discontinuation of therapy. Some patients experienced ongoing or new serious adverse events during the 6-month follow-up period. In the PegIntron™/REBETOL trial, 13 patients experienced life-threatening psychiatric events (suicidal ideation or attempt) and one patient accomplished suicide.

There have been five patient deaths which occurred in clinical trials: one suicide in a patient receiving PegIntron™ monotherapy and one suicide in a patient receiving PegIntron™/REBETOL combination therapy; two deaths among patients receiving INTRON A monotherapy (1 murder/suicide and 1 sudden death) and one patient death in the INTRON A/REBETOL group (motor vehicle accident).

Overall, 10-14% of patients receiving PegIntron™, alone or in combination with REBETOL, discontinued therapy compared with 6% treated with INTRON A alone and 13% treated with INTRON A in combination with REBETOL. The most
common reasons for discontinuation of therapy were related to psychiatric, systemic
(eg, fatigue, headache), or gastrointestinal adverse events.

In the combination therapy trial, dose reductions due to adverse reactions
occurred in 42% of patients receiving PegIntron™ (1.5 mcg/kg)/REBETOL and in
34% of those receiving INTRON A/REBETOL. The majority of patients (57%)
weighing 60 kg or less receiving PegIntron™ (1.5 mcg/kg)/REBETOL required dose
reduction. Reduction of interferon was dose related (PegIntron™ 1.5 mcg/kg >
PegIntron™ 0.5 mcg/kg or INTRON A), 40%, 27%, 28%, respectively. Dose
reduction for REBETOL was similar across all three groups, 33-35%. The most
common reasons for dose modifications were neutropenia (18%), or anemia (9%)
(see Laboratory Values). Other common reasons included depression, fatigue,
nausea, and thrombocytopenia.

In the PegIntron™/REBETOL combination trial the most common adverse
events were psychiatric which occurred among 77% of patients and included most
commonly depression, irritability, and insomnia, each reported by approximately 30-
40% of subjects in all treatment groups. Suicidal behavior (ideation, attempts, and
suicides) occurred in 2% of all patients during treatment or during follow-up after
treatment cessation (see WARNINGS).

PegIntron™ induced fatigue or headache in approximately two-thirds of
patients, and induced fever or rigors in approximately half of the patients. The
severity of some of these systemic symptoms (eg, fever and headache) tended to
decrease as treatment continues. The incidence tends to be higher with
PegIntron™ than with INTRON A therapy alone or in combination with REBETOL.

Application site inflammation and reaction (eg, bruise, itchiness, irritation)
occurred at approximately twice the incidence with PegIntron™ therapies (in up to
75% of patients) compared with INTRON A. However, injection site pain was
infrequent (2-3%) in all groups.

Other common adverse events in the PegIntron™/REBETOL group included
myalgia (56%), arthralgia (34%), nausea (43%), anorexia (32%), weight loss (29%),
alopecia (36%), and pruritus (29%).
In the PegIntron™ monotherapy trial the incidence of severe adverse events was 13% in the INTRON A group and 17% in the PegIntron™ groups. In the PegIntron™/REBETOL combination therapy trial, the incidence of severe adverse events was 23% in the INTRON A/REBETOL group and 31-34% in the PegIntron™/REBETOL groups. The incidence of life-threatening adverse events was ≤ 1% across all groups in the monotherapy and combination therapy trials.

Adverse events that occurred in the clinical trial at >5% incidence are provided in Table 3 by treatment group. Due to potential differences in ascertainment procedures, adverse event rate comparisons across studies should not be made.

**Table 3. Adverse Events Occurring in > 5% of Patients**

<table>
<thead>
<tr>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse Events</strong></td>
<td>PegIntron™ 1 mcg/kg (n=297)</td>
</tr>
<tr>
<td>Application Site</td>
<td>INTRON A 3 MIU (n=303)</td>
</tr>
<tr>
<td>Injection Site</td>
<td>47</td>
</tr>
<tr>
<td>Inflammation/Reactions</td>
<td>20</td>
</tr>
<tr>
<td>Autonomic Nervous Sys.</td>
<td></td>
</tr>
<tr>
<td>Mouth Dry</td>
<td>6</td>
</tr>
<tr>
<td>Sweating Increased</td>
<td>6</td>
</tr>
<tr>
<td>Flushing</td>
<td>6</td>
</tr>
<tr>
<td>Body as a Whole</td>
<td></td>
</tr>
<tr>
<td>Fatigue/Asthenia</td>
<td>52</td>
</tr>
<tr>
<td>Headache</td>
<td>56</td>
</tr>
<tr>
<td>Rigors</td>
<td>23</td>
</tr>
<tr>
<td>Fever</td>
<td>22</td>
</tr>
<tr>
<td>Weight Decrease</td>
<td>11</td>
</tr>
<tr>
<td>RUQ Pain</td>
<td>8</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>6</td>
</tr>
<tr>
<td>Malaise</td>
<td>7</td>
</tr>
<tr>
<td>Central/Periph. Nerv. Sys.</td>
<td></td>
</tr>
<tr>
<td>Adverse Events</td>
<td>Study 1 PegIntron™ 1 mcg/kg (n=297)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Dizziness</td>
<td>12</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>5</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>26</td>
</tr>
<tr>
<td>Anorexia</td>
<td>20</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>18</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>15</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>6</td>
</tr>
<tr>
<td>Constipation</td>
<td>1</td>
</tr>
<tr>
<td><strong>Hematologic Disorders</strong></td>
<td></td>
</tr>
<tr>
<td>Neutropenia</td>
<td>6</td>
</tr>
<tr>
<td>Anemia</td>
<td>0</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>7</td>
</tr>
<tr>
<td><strong>Liver and Biliary System</strong></td>
<td></td>
</tr>
<tr>
<td>Hepatomegaly</td>
<td>6</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
</tr>
<tr>
<td>Myalgia</td>
<td>54</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>23</td>
</tr>
<tr>
<td>Musculoskeletal Pain</td>
<td>28</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>23</td>
</tr>
<tr>
<td>Depression</td>
<td>29</td>
</tr>
<tr>
<td>Anxiety/Emotional Lability/Impairability</td>
<td>28</td>
</tr>
<tr>
<td>Concentration Impaired</td>
<td>10</td>
</tr>
<tr>
<td>Agitation</td>
<td>2</td>
</tr>
<tr>
<td>Nervousness</td>
<td>4</td>
</tr>
<tr>
<td><strong>Reproductive, Female</strong></td>
<td></td>
</tr>
<tr>
<td>Menstrual Disorder</td>
<td>4</td>
</tr>
<tr>
<td><strong>Resistance Mechanism</strong></td>
<td></td>
</tr>
<tr>
<td>Infection Viral</td>
<td>11</td>
</tr>
<tr>
<td>Infection Fungal</td>
<td>&lt;1</td>
</tr>
<tr>
<td><strong>Respiratory System</strong></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>4</td>
</tr>
</tbody>
</table>
### Percentage of Patients Reporting Adverse Events*

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>PegIntron™ 1 mcg/kg (n=297)</th>
<th>INTRON A 3 MIU (n=303)</th>
<th>PegIntron™ 1.5 mcg/kg/REBETOL (n=511)</th>
<th>INTRON A/REBETOL (n=505)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coughing</td>
<td>8</td>
<td>5</td>
<td>23</td>
<td>16</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>10</td>
<td>7</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>7</td>
<td>7</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td><strong>Skin and Appendages</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>22</td>
<td>22</td>
<td>36</td>
<td>32</td>
</tr>
<tr>
<td>Pruritus</td>
<td>12</td>
<td>8</td>
<td>29</td>
<td>28</td>
</tr>
<tr>
<td>Rash</td>
<td>6</td>
<td>7</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>Skin Dry</td>
<td>11</td>
<td>9</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td><strong>Special Senses Other,</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taste Perversion</td>
<td>&lt;1</td>
<td>2</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td><strong>Vision Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td>2</td>
<td>3</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

*Patients reporting one or more adverse events. A patient may have reported more than one adverse event within a body system/organ class category.

Many patients continued to experience adverse events several months after discontinuation of therapy. By the end of the 6-month follow-up period, the incidence of ongoing adverse events by body class in the PegIntron™ 1.5/REBETOL group was 33% (psychiatric), 20% (musculoskeletal), and 10% (for endocrine and for GI). In approximately 10-15% of patients weight loss, fatigue, and headache had not resolved.

Individual serious adverse events occurred at a frequency ≤1% and included suicide attempt, suicidal ideation, severe depression; psychosis, aggressive reaction, relapse of drug addiction/overdose; nerve palsy (facial, oculomotor); cardiomyopathy, myocardial infarction, angina, pericardial effusion, retinal ischemia, retinal artery or vein thrombosis, blindness, decreased visual acuity, optic neuritis, transient ischemic attack, supraventricular arrhythmias, loss of consciousness; neutropenia, infection (sepsis, pneumonia, abscess, cellulitis); emphysema, bronchiolitis obliterans, pleural effusion, gastroenteritis, pancreatitis, gout, hyperglycemia, hyperthyroidism and hypothyroidism, autoimmune thrombocytopenia with or without purpura, rheumatoid arthritis, interstitial nephritis, lupus-like...
syndrome, sarcoidosis, aggravated psoriasis; urticaria, injection-site necrosis, vasculitis, phototoxicity.

Laboratory Values

Changes in selected laboratory values during treatment with PegIntron™ alone or in combination with REBETOL treatment are described below. Decreases in hemoglobin, neutrophils, and platelets may require dose reduction or permanent discontinuation from therapy. (See DOSAGE AND ADMINISTRATION: Dose Reduction.)

Hemoglobin. REBETOL induced a decrease in hemoglobin levels in approximately two thirds of patients. Hemoglobin levels decreased to <11g/dL in about 30% of patients. Severe anemia (<8 g/dL) occurred in <1% of patients. Dose modification was required in 9% and 13% of patients in the PegIntron™/REBETOL and INTRON A /REBETOL groups. Hemoglobin levels become stable by treatment week 4-6 on average. Hemoglobin levels return to baseline between 4 and 12 weeks post-treatment. In the PegIntron™ monotherapy trial, hemoglobin decreases were generally mild and dose modifications were rarely necessary (see DOSAGE AND ADMINISTRATION: Dose Reduction).

Neutrophils. Decreases in neutrophil counts were observed in a majority of patients treated with PegIntron™ alone (70%) or as combination therapy with REBETOL (85%) and INTRON A/REBETOL (60%). Severe potentially life-threatening neutropenia (<0.5 x 10^9/L) occurred in 1% of patients treated with PegIntron™ monotherapy, 2% of patients treated with INTRON A/REBETOL, and in 4% of patients treated with PegIntron™/REBETOL. Two percent of patients receiving PegIntron™ monotherapy and 18% of patients receiving PegIntron™ /REBETOL required modification of interferon dosage. Few patients (< 1%) required permanent discontinuation of treatment. Neutrophil counts generally return to pre-treatment levels within 4 weeks of cessation of therapy. (See DOSAGE AND ADMINISTRATION: Dose Reduction.)

Platelets. Platelet counts decrease in approximately 20% of patients treated with PegIntron™ alone or with REBETOL and in 6% of patients treated with INTRON
A/REBETOL. Severe decreases in platelet counts (<50,000/mm³) occur in <1% of patients. Patients may require discontinuation or dose modification as a result of platelet decreases. (See DOSAGE AND ADMINISTRATION: Dose Reduction.) In the PegIntron™/REBETOL combination therapy trial, 1% or 3% of patients required dose modification of INTRON A or PegIntron™, respectively. Platelet counts generally returned to pre-treatment levels within 4 weeks of the cessation of therapy.

Triglycerides. Elevated triglyceride levels have been observed in patients treated with interferon alfas including PegIntron™.

Thyroid Function. Development of TSH abnormalities, with and without clinical manifestations, are associated with interferon therapies. Clinically apparent thyroid disorders occur among patients treated with either INTRON A or PegIntron™ (with or without REBETOL) at a similar incidence (5% for hypothyroidism and 3% for hyperthyroidism). Subjects developed new onset TSH abnormalities while on treatment and during the follow-up period. At the end of the follow-up period, 7% of subjects still had abnormal TSH values.

Bilirubin and uric acid. In the PegIntron™/REBETOL trial, 10-14% of patients developed hyperbilirubinemia and 33-38% developed hyperuricemia in association with hemolysis. Six patients developed mild to moderate gout.

Postmarketing Experience

The following adverse reactions have been identified and reported during post-approval use of PegIntron™ therapy: aphthous stomatitis, erythema multiforme, hearing impairment, hearing loss, memory loss, migraine headache, myositis, peripheral neuropathy, renal insufficiency, renal failure, rhabdomyolysis, seizures, Stevens Johnson syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, vertigo. Because the reports of these reactions are voluntary and the population of uncertain size, it is not always possible to reliably estimate the frequency of the reaction or establish a causal relationship to drug exposure.

Immunogenicity: Approximately 2% of patients receiving PegIntron™ (32/1759) or INTRON A (11/728) with or without REBETOL developed low-titer (≤160) neutralizing antibodies to PegIntron™ or INTRON A. The clinical and pathological
significance of the appearance of serum neutralizing antibodies is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The incidence of posttreatment-binding antibody ranged from 8 to 15 percent. The data reflect the percentage of patients whose test results were considered positive for antibodies to PegIntron™ in a Biacore assay that is used to measure binding antibodies, and in an antiviral neutralization assay, which measures serum-neutralizing antibodies. The percentage of patients whose test results were considered positive for antibodies is highly dependent on the sensitivity and specificity of the assays. Additionally, the observed incidence of antibody positivity in these assays may be influenced by several factors including sample timing and handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to PegIntron™ with the incidence of antibodies to other products may be misleading.

OVERDOSAGE

There is limited experience with overdosage. In the clinical studies, a few patients accidentally received a dose greater than that prescribed. There were no instances in which a participant in the monotherapy or combination therapy trials received more than 10.5 times the intended dose of PegIntron™. The maximum dose received by any patient was 3.45 mcg/kg weekly over a period of approximately 12 weeks. The maximum known overdosage of REBETOL was an intentional ingestion of 10 g (fifty 200-mg capsules). There were no serious reactions attributed to these overdosages. In cases of overdosing, symptomatic treatment and close observation of the patient are recommended.

DOSAGE AND ADMINISTRATION

There are no safety and efficacy data on treatment for longer than one year. A patient should self-inject PegIntron™ only if it has been determined that it is appropriate and the patient agrees to medical follow-up as necessary and training in proper injection technique has been given to him/her.
It is recommended that patients receiving PegIntron™, alone or in combination with ribavirin, be discontinued from therapy if HCV viral levels remain high after 6 months of therapy.

**PegIntron™ Monotherapy**

The recommended dose of PegIntron™ regimen is 1 mcg/kg/week subcutaneously for one year. The dose should be administered on the same day of the week. The volume of PegIntron™ to be injected depends on patient weight (see Table 4 below).

**Table 4 Recommended PegIntron™ Monotherapy Dosing**

<table>
<thead>
<tr>
<th>Body weight kg</th>
<th>PegIntron™ Redipen® or Vial Strength to Use</th>
<th>Amount of PegIntron™ (mcg) To Administer</th>
<th>Volume (mL) of PegIntron™ to Administer</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤45</td>
<td>50 mcg per 0.5 mL</td>
<td>40</td>
<td>0.4</td>
</tr>
<tr>
<td>46 - 56</td>
<td></td>
<td>50</td>
<td>0.5</td>
</tr>
<tr>
<td>57 - 72</td>
<td>80 mcg per 0.5 mL</td>
<td>64</td>
<td>0.4</td>
</tr>
<tr>
<td>73 – 88</td>
<td></td>
<td>80</td>
<td>0.5</td>
</tr>
<tr>
<td>89 – 106</td>
<td>120 mcg per 0.5 mL</td>
<td>96</td>
<td>0.4</td>
</tr>
<tr>
<td>107 - 136</td>
<td></td>
<td>120</td>
<td>0.5</td>
</tr>
<tr>
<td>137 - 160</td>
<td>150 mcg per 0.5 mL</td>
<td>150</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* When reconstituted as directed.

**PegIntron™/REBETOL Combination Therapy**

When administered in combination with REBETOL, the recommended dose of PegIntron™ is 1.5 micrograms/kg/week. The volume of PegIntron™ to be injected depends on the strength of PegIntron™ and patient’s body weight. (See Table 5.)
TABLE 5. Recommended PegIntron™ Combination Therapy Dosing

<table>
<thead>
<tr>
<th>Body weight kg</th>
<th>PegIntron™ Redipen® or Vial Strength to Use</th>
<th>Amount of PegIntron™ (mcg) To Administer</th>
<th>Volume (mL)* of PegIntron™ to Administer</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>50 mcg per 0.5 mL</td>
<td>50</td>
<td>0.5</td>
</tr>
<tr>
<td>40-50</td>
<td>80 mcg per 0.5 mL</td>
<td>64</td>
<td>0.4</td>
</tr>
<tr>
<td>51-60</td>
<td></td>
<td>80</td>
<td>0.5</td>
</tr>
<tr>
<td>61-75</td>
<td>120 mcg per 0.5 mL</td>
<td>96</td>
<td>0.4</td>
</tr>
<tr>
<td>76-85</td>
<td></td>
<td>120</td>
<td>0.5</td>
</tr>
<tr>
<td>&gt;85</td>
<td>150 mcg per 0.5 mL</td>
<td>150</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* When reconstituted as directed.

The recommended dose of REBETOL is 800 mg/day in 2 divided doses: two capsules (400 mg) with breakfast and two capsules (400 mg) with dinner. REBETOL should not be used in patients with creatinine clearance <50 mL/min.

Dose Reduction

If a serious adverse reaction develops during the course of treatment (see WARNINGS) discontinue or modify the dosage of PegIntron™ and/or REBETOL until the adverse event abates or decreases in severity. If persistent or recurrent serious adverse events develop despite adequate dosage adjustment, discontinue treatment. For guidelines for dose modifications and discontinuation based on laboratory parameters, see Tables 6 and 7. Dose reduction of PegIntron™ may be accomplished by utilizing a lower dose strength as shown in Table 8 or 9. For vials, 50% dose reduction may also be accomplished by reducing the volume administered by one-half without changing the dose strength.
In the combination therapy trial, dose reductions occurred among 42% of patients receiving PegIntron™ 1.5 mcg/kg/REBETOL 800 mg daily including 57% of those patients weighing 60 kg or less (see ADVERSE REACTIONS).

Table 6: Guidelines for Modification or Discontinuation of PegIntron™ or PegIntron™/REBETOL and for Scheduling Visits for Patients with Depression

<table>
<thead>
<tr>
<th>Depression Severity</th>
<th>Initial Management (4-8 wks)</th>
<th>Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose modification</td>
<td>Visit schedule</td>
</tr>
<tr>
<td>Mild</td>
<td>No change</td>
<td>Evaluate once weekly by visit and/or phone.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Decrease IFN dose 50%</td>
<td>Evaluate once weekly (office visit at least every other week).</td>
</tr>
<tr>
<td>Severe</td>
<td>Discontinue IFN/R permanently.</td>
<td>Obtain immediate psychiatric consultation.</td>
</tr>
</tbody>
</table>

1 See DSM-IV for definitions.

Table 7. Guidelines for Dose Modification and Discontinuation of PegIntron™ or PegIntron™/REBETOL for Hematologic Toxicity

<table>
<thead>
<tr>
<th>Laboratory Values</th>
<th>PegIntron™</th>
<th>REBETOL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hgb*</td>
<td>&lt;10.0 g/dL</td>
<td>---------</td>
</tr>
<tr>
<td>&lt;8.5 g/dL</td>
<td>Permanently discontinue</td>
<td>Decrease by 200mg/day</td>
</tr>
<tr>
<td>WBC</td>
<td>&lt;1.5 x10^9/L</td>
<td>Reduce dose by 50%</td>
</tr>
<tr>
<td>&lt;1.0 x10^9/L</td>
<td>Permanently discontinue</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Neutrophil</td>
<td>&lt;0.75 x10^9/L</td>
<td>Reduce dose by 50%</td>
</tr>
<tr>
<td>&lt;0.5 x10^9/L</td>
<td>Permanently discontinue</td>
<td>Permanently discontinue</td>
</tr>
<tr>
<td>Platelets</td>
<td>&lt;80 x10^9/L</td>
<td>Reduce dose by 50%</td>
</tr>
<tr>
<td>&lt;50 x10^9/L</td>
<td>Permanently discontinue</td>
<td>Permanently discontinue</td>
</tr>
</tbody>
</table>
For patients with a history of stable cardiac disease receiving PegIntron™ in combination with ribavirin, the PegIntron™ dose should be reduced by half and the ribavirin dose by 200 mg/day if a > 2g/dL decrease in hemoglobin is observed during any 4-week period. Both PegIntron™ and ribavirin should be permanently discontinued if patients have hemoglobin levels <12 g/dL after this ribavirin dose reduction.

**Table 8. Reduced PegIntron™ Dose (0.5mcg /kg) for (1mcg /kg) Monotherapy**

<table>
<thead>
<tr>
<th>Body weight kg</th>
<th>PegIntron™ Redipen®/Vial Strength to Use</th>
<th>Amount of PegIntron™ (mcg) To Administer</th>
<th>Volume (mL)** of PegIntron™ to Administer</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤45</td>
<td>50 mcg per 0.5 mL*</td>
<td>20</td>
<td>0.2</td>
</tr>
<tr>
<td>46 - 56</td>
<td>50 mcg per 0.5 mL</td>
<td>25</td>
<td>0.25</td>
</tr>
<tr>
<td>57 - 72</td>
<td>50 mcg per 0.5 mL</td>
<td>30</td>
<td>0.3</td>
</tr>
<tr>
<td>73 – 88</td>
<td>50 mcg per 0.5 mL</td>
<td>40</td>
<td>0.4</td>
</tr>
<tr>
<td>89-106</td>
<td>50 mcg per 0.5 mL</td>
<td>50</td>
<td>0.5</td>
</tr>
<tr>
<td>107-136</td>
<td>80 mcg per 0.5 mL</td>
<td>64</td>
<td>0.4</td>
</tr>
<tr>
<td>137-160</td>
<td>80 mcg per 0.5 mL</td>
<td>80</td>
<td>0.5</td>
</tr>
</tbody>
</table>

*Must use vial. Minimum delivery for Redipen® 0.3 mL.*

**When reconstituted as directed.
### TABLE 9. Reduced PegIntron™ Dose (0.75 mcg/kg) for (1.5 mcg/kg) Combination Therapy

<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>PegIntron™ Redipen®/Vial Strength to Use</th>
<th>Amount of PegIntron™(mcg) to Administer</th>
<th>Volume (mL)** of PegIntron™ to Administer</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;40</td>
<td>50 mcg per 0.5 ml*</td>
<td>25</td>
<td>0.25</td>
</tr>
<tr>
<td>40-50</td>
<td>50 mcg per 0.5 ml</td>
<td>30</td>
<td>0.3</td>
</tr>
<tr>
<td>51-60</td>
<td>50 mcg per 0.5 ml</td>
<td>40</td>
<td>0.4</td>
</tr>
<tr>
<td>61-75</td>
<td>50 mcg per 0.5 ml</td>
<td>50</td>
<td>0.5</td>
</tr>
<tr>
<td>76-85</td>
<td>80 mcg per 0.5 ml</td>
<td>64</td>
<td>0.4</td>
</tr>
<tr>
<td>&gt;85</td>
<td></td>
<td>80</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* Must use vial. Minimum delivery for Redipen® 0.3 mL

** When reconstituted as directed

### Renal Function

In patients with moderate renal dysfunction (creatinine clearance 30-50 mL/min), the PegIntron™ dose should be reduced by 25%. Patients with severe renal dysfunction (creatinine clearance 10-29 mL/min) including those on hemodialysis, should have the PegIntron™ dose reduced by 50%. If renal function decreases during treatment, PegIntron™ therapy should be discontinued.

### Preparation and Administration

**PegIntron™ Redipen®**

PegIntron™ Redipen® consists of a dual-chamber glass cartridge with sterile, lyophilized peginterferon alfa-2b in the active chamber and Sterile Water for Injection, USP in the diluent chamber. The PegIntron™ in the glass cartridge should appear as a white to off-white tablet shaped solid that is whole or in pieces, or powder. To reconstitute the lyophilized peginterferon alfa-2b in the Redipen®, hold...
the Redipen® upright (dose button down) and press the two halves of the pen together until there is an audible click. Gently invert the pen to mix the solution. **DO NOT SHAKE.** The reconstituted solution has a concentration of either 50 mcg per 0.5 mL, 80 mcg per 0.5 mL, 120 mcg per 0.5 mL, or 150 mcg per 0.5 mL for a single subcutaneous injection. Visually inspect the solution for particulate matter and discoloration prior to administration. The reconstituted solution should be clear and colorless. Do not use if the solution is discolored or cloudy, or if particulates are present.

Keeping the pen upright, attach the supplied needle and select the appropriate PegIntron™ dose by pulling back on the dosing button until the dark bands are visible and turning the button until the dark band is aligned with the correct dose. The prepared PegIntron™ solution is to be injected subcutaneously.

The PegIntron™ Redipen® is a single-use pen and does not contain a preservative. The reconstituted solution should be used immediately and cannot be stored for more than 24 hours at 2°-8° C (see **Storage**). **DO NOT REUSE THE REDIPEN®.** The sterility of any remaining product can no longer be guaranteed. **DISCARD THE UNUSED PORTION.** Pooling of unused portions of some medications has been linked to bacterial contamination and morbidity.

**PegIntron™ Vials**

Two B-D® Safety Lok™ syringes are provided in the package; one syringe is for the reconstitution steps and one for the patient injection. There is a plastic safety sleeve to be pulled over the needle after use. The syringe locks with an audible click when the green stripe on the safety sleeve covers the red stripe on the needle.

Instructions for the preparation and administration of PegIntron™ Powder for Injection are provided below.

**Reconstitute the PegIntron™ lyophilized product with only 0.7 mL of 1.25 mL of supplied diluent (Sterile Water for Injection, USP). The diluent vial is for single use only. The remaining diluent should be discarded.** No other medications should be added to solutions containing PegIntron™, and PegIntron™ should not be reconstituted with other diluents. Swirl gently to hasten complete
dissolution of the powder. The reconstituted solution should be clear and colorless. Visually inspect the solution for particulate matter and discoloration prior to administration. The solution should not be used if discolored or cloudy, or if particulates are present.

The appropriate PegIntron™ dose should be withdrawn and injected subcutaneously. PegIntron™ vials are for single use only and do not contain a preservative. The reconstituted solution should be used immediately and cannot be stored for more than 24 hours at 2°-8° C (see Storage). DO NOT REUSE THE VIAL. The sterility of any remaining product can longer be guaranteed. DISCARD THE UNUSED PORTION. Pooling of unused portions of some medications has been linked to bacterial contamination and morbidity.

After preparation and administration of the PegIntron™ for injection, it is essential to follow the state and/or local procedures for proper disposal of syringes, needles, and the Redipen®. A puncture-resistant container should be used for disposal. Patients should be instructed in how to properly dispose of used syringes, needles, or the Redipen® and be cautioned against the reuse of these items.

Storage

**PegIntron™ Redipen®**

PegIntron™ Redipen® should be stored at 2°- 8°C (36°-46°F).

After reconstitution, the solution should be used immediately, but may be stored up to 24 hours at 2° - 8°C (36° - 46°F). The reconstituted solution contains no preservative, and is clear and colorless. **DO NOT FREEZE.**

**PegIntron™ Vials**

PegIntron™, should be stored at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. After reconstitution with supplied Diluent the solution should be used immediately, but may be stored up to 24 hours at 2°-8°C (36°-46°F). The reconstituted solution contains no preservative, is clear and colorless. **DO NOT FREEZE.**
### HOW SUPPLIED

#### PegIntron™ Redipen®

<table>
<thead>
<tr>
<th>PegIntron™ Redipen® Package Contains:</th>
<th>(NDC Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A box containing one 50 mcg per 0.5 mL PegIntron™ Redipen® and 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1323-01</td>
</tr>
<tr>
<td>A box containing one 80 mcg per 0.5 mL PegIntron™ Redipen® and 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1316-01</td>
</tr>
<tr>
<td>A box containing one 120 mcg per 0.5 mL PegIntron™ Redipen® and 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1297-01</td>
</tr>
<tr>
<td>A box containing one 150 mcg per 0.5 mL PegIntron™ Redipen® and 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1370-01</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PegIntron™ Redipen® PAK 4 Contains:</th>
<th>(NDC Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A box containing four 50 mcg per 0.5 mL PegIntron™ Redipen® units, each containing 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1323-02</td>
</tr>
<tr>
<td>A box containing four 80 mcg per 0.5 mL PegIntron™ Redipen® units, each containing 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1316-02</td>
</tr>
<tr>
<td>A box containing four 120 mcg per 0.5 mL PegIntron™ Redipen® units, each containing 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1297-02</td>
</tr>
<tr>
<td>A box containing four 150 mcg per 0.5 mL PegIntron™ Redipen® units, each containing 1 B-D® needle and 2 alcohol swabs.</td>
<td>0085-1370-02</td>
</tr>
</tbody>
</table>

#### PegIntron™ Vials

<table>
<thead>
<tr>
<th>PegIntron™ Package Contains:</th>
<th>(NDC Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A box containing one 50 mcg per 0.5 mL vial of PegIntron™ Powder for Injection and one 1.25 mL vial of Diluent (Sterile Water for Injection, USP), 2 B-D® Safety Lok™ syringes with a safety sleeve and 2 alcohol swabs.</td>
<td>0085-1368-01</td>
</tr>
<tr>
<td>A box containing one 80 mcg per 0.5 mL vial of PegIntron™ Powder for Injection and one 1.25 mL vial of Diluent (Sterile Water for Injection, USP), 2 B-D® Safety Lok™ syringes with a safety sleeve and 2 alcohol swabs.</td>
<td>0085-1291-01</td>
</tr>
<tr>
<td>A box containing one 120 mcg per 0.5 mL vial of PegIntron™ Powder for Injection and one 1.25 mL vial of Diluent (Sterile Water for Injection, USP), 2 B-D® Safety Lok™ syringes with a safety sleeve and 2 alcohol swabs.</td>
<td>0085-1304-01</td>
</tr>
</tbody>
</table>
A box containing one 150 mcg per 0.5 mL vial of PegIntron™ Powder for Injection and one 1.25 mL vial of Diluent (Sterile Water for Injection, USP), 2 B-D® Safety Lok™ syringes with a safety sleeve and 2 alcohol swabs. (NDC 0085-1279-01)
MEDICATION GUIDE

PegIntron™

Peginterferon alfa-2b

Including appendix with instructions for using PegIntron™ Powder for Injection

Read this Medication Guide carefully before you start taking PegIntron™ (Peg In-tron) or PegIntron™/REBETOL (REB-eh-tole) combination therapy. Read the Medication Guide each time you refill your prescription because there may be new information. The information in this Medication Guide does not take the place of talking with your health care provider (doctor, nurse, nurse practitioner, or physician’s assistant).

If you are taking PegIntron™/REBETOL combination therapy, also read the Medication Guide for REBETOL (ribavirin, USP) Capsules.

What is the most important information I should know about PegIntron™ and PegIntron™/REBETOL combination therapy?

PegIntron™ (peginterferon) is a treatment for some people who are infected with hepatitis C virus. However, PegIntron™ and PegIntron™/REBETOL combination therapy can have serious side effects that may cause death in rare cases. Before you decide to start treatment, you should talk to your health care provider about the possible benefits and side effects of PegIntron™ or PegIntron™/REBETOL combination therapy. If you begin treatment you will need to see your health care provider regularly for medical examinations and lab tests to make sure your treatment is working and to check for side effects.

REBETOL capsules may cause birth defects and/or death of an unborn child. If you are pregnant, you or your male partner must not take PegIntron™/REBETOL combination therapy. You must not become pregnant while either you or your partner are being treated with the combination PegIntron™/REBETOL therapy, or for 6 months after stopping therapy. Men and women should use birth control while taking the combination therapy and for 6 months afterwards. If you or your partner are being treated and you become pregnant, either during treatment or within 6 months of stopping treatment, call your health care provider right away.

If you are taking PegIntron™ or PegIntron™/REBETOL therapy you should call your health care provider immediately if you develop any of these symptoms:

New or worsening mental health problems, such as thoughts about killing or hurting yourself or others, trouble breathing, chest pain, severe stomach or lower back pain, bloody diarrhea or bloody bowel movements, high fever, bruising, bleeding, or decreased vision.

The most serious possible side effects of PegIntron™ and PegIntron™/REBETOL therapy include:
Problems with Pregnancy. Combination PegIntron™/REBETOL therapy can cause death, serious birth defects, or other harm to your unborn child. If you are a woman of childbearing age, you must not become pregnant during treatment and for 6 months after you have stopped therapy. You must have a negative pregnancy test immediately before beginning treatment, during treatment and for 6 months after you have stopped therapy. Both males and female patients must use effective forms of birth control during treatment and for the 6 months after treatment is completed. Male patients should use a condom. If you are a female, you must use birth control even if you believe that you are not fertile or that your fertility is low. You should talk to your health care provider about birth control for you and your partner.

Mental health problems and suicide. PegIntron™ and PegIntron™/REBETOL therapies may cause patients to develop mood or behavioral problems. These can include irritability (getting easily upset) and depression (feeling low, feeling bad about yourself, or feeling hopeless). Some patients may have aggressive behavior. Former drug addicts may fall back into drug addiction or overdose. Some patients think about hurting or killing themselves or other people and some have killed (suicide) or hurt themselves or others. You must tell your health care provider if you are being treated for a mental illness or had treatment in the past for any mental illness, including depression and suicidal behavior. You should tell your health care provider if you have ever been addicted to drugs or alcohol.

Heart problems. Some patients taking PegIntron™ or PegIntron™/REBETOL therapy may develop problems with their heart, including low blood pressure, fast heart rate, and very rarely, heart attacks. Tell your health care provider if you have had any heart problems in the past.

Blood problems. PegIntron™ and PegIntron™/REBETOL therapies commonly lower two types of blood cells (white blood cells and platelets). In some patients, these blood counts may fall to dangerously low levels. If your blood counts become very low, this could lead to infections or bleeding.

REBETOL therapy causes a decrease in the number of red blood cells you have (anemia). This can be dangerous, especially for patients who already have heart or circulatory (cardiovascular) problems. Talk with your health care provider before taking combination PegIntron™/REBETOL therapy if you have, or have ever had any cardiovascular problems.

Body organ problems. Certain symptoms like severe stomach pain may mean that your internal organs are being damaged.

For other possible side effects, see “What are the possible side effects of PegIntron™ and PegIntron™/REBETOL” in this Medication Guide.

What is PegIntron™ and PegIntron™/REBETOL combination therapy? The PegIntron™ product is a drug used to treat adults who have a lasting (chronic) infection with hepatitis C virus and who show signs that the virus is damaging the liver.
PegIntron™/REBETOL combination therapy consists of two medications also used to treat hepatitis C infection. Patients with hepatitis C have the virus in their blood and in their liver. PegIntron™ reduces the amount of virus in the body and helps the body's immune system fight the virus. REBETOL (ribavirin) is a drug that helps to fight the viral infection but does not work when used by itself to treat chronic hepatitis C.

It is not known if PegIntron™ or PegIntron™/REBETOL therapies can cure hepatitis C (permanently eliminate the virus), or if it can prevent liver failure or liver cancer that is caused by hepatitis C infection.

It is also not known if PegIntron™ or PegIntron™/REBETOL combination therapy will prevent one infected person from infecting another person with hepatitis C.

**Who should not take PegIntron™ or PegIntron™/REBETOL therapy?**

Do not take PegIntron™ or PegIntron™/REBETOL therapy if you:

- are pregnant, planning to get pregnant during treatment or during the 6 months after treatment, or breast-feeding
- are a male patient with a female sexual partner who is pregnant or plans to become pregnant at any time while you are being treated with REBETOL or during the 6 months after your treatment has ended.
- have hepatitis caused by your immune system attacking your liver (autoimmune hepatitis) or unstable liver disease
- had an allergic reaction to another alpha interferon or are allergic to any of the ingredients in PegIntron™ or REBETOL Capsules. If you have any doubts, ask your health care provider.
- Do not take PegIntron™/REBETOL combination therapy if you have abnormal red blood cells such as sickle-cell anemia or thalassemia major.

If you have any of the following conditions or serious medical problems, discuss them with your health care provider before taking PegIntron™ or PegIntron™/REBETOL therapy:

- depression or anxiety
- sleep problems
- high blood pressure
- previous heart attack, or other heart problems
- liver problems (other than hepatitis C infection)
- any kind of autoimmune disease (where the body’s immune system attacks the body’s own cells), such as psoriasis, systemic lupus erythematous, rheumatoid arthritis
- thyroid problems
- diabetes
- colitis (inflammation of the bowels)
How should I take PegIntron™ or PegIntron™/REBETOL?

Your health care provider will decide whether you will take PegIntron™ therapy alone or the combination of PegIntron™/REBETOL, as well as the correct dose (based on your weight). PegIntron™ and PegIntron™/REBETOL are given for one year. Take your prescribed dose of PegIntron™ ONCE A WEEK, on the same day of each week and at approximately the same time. Take the medicine for the full year and do not take more than the prescribed dose. REBETOL Capsules should be taken with food. When you take REBETOL with food, more of the medicine (70% more on average) is taken up by your body. You should take REBETOL the same way every day (twice a day with food) to keep the medicine in your body at a steady level. This will help your health care provider to decide how your treatment is working and how to change the number of REBETOL capsules you take if you have side effects from REBETOL. **Be sure to read the Medication Guide for REBETOL (ribavirin, USP) for complete instructions on how to take the REBETOL capsules.**

You should be completely comfortable with how to prepare PegIntron™, how to set the dose you take, and how to inject yourself before you use PegIntron™ for the first time. PegIntron™ comes in two different forms, a powder in a single-use vial and a Redipen® single-use delivery system. See the attached appendix for detailed instructions for preparing and giving a dose of PegIntron™.

If you miss a dose of the PegIntron™ product, take the missed dose as soon as possible during the same day or the next day, then continue on your regular dosing schedule. If several days go by after you miss a dose, check with your health care provider about what to do. Do not double the next dose or take more than one dose a week without talking to your health care provider. Call your health care provider right away if you take more than your prescribed PegIntron™ dose. Your health care provider may wish to examine you more closely, and take blood for testing.

If you miss a dose of REBETOL capsules, take the missed dose as soon as possible during the same day. If an entire day has gone by, check with your health care provider about what to do. Do not double the next dose.

You must get regular blood tests to help your health care provider check how the treatment is working and to check for side effects.
Tell your health care provider if you are taking or planning to take other prescription or non-prescription medicines, including vitamin and mineral supplements and herbal medicines.

What should I avoid while taking PegIntron™ or PegIntron™/REBETOL therapies?

- If you are pregnant do not start taking PegIntron™/REBETOL combination therapy.
- Avoid becoming pregnant while taking PegIntron™ or PegIntron™/REBETOL.

PegIntron™ and PegIntron™/REBETOL may harm your unborn child (death or serious birth defects) or cause you to lose your baby (miscarry). If you or your partner becomes pregnant during treatment or during the 6 months after treatment with PegIntron™/REBETOL combination therapy, immediately report the pregnancy to your health care provider. You or your health care provider should call (800) 727-7064. By calling this number, information about you and/or your partner will be added to a pregnancy registry that will be used to help you and your health care provider make decisions about your treatment for hepatitis in the future. You, your partner and/or your health care provider will be asked to provide follow-up information on the outcome of the pregnancy.

- Do not breast-feed your baby while taking PegIntron™.

What are the possible side effects of PegIntron™ and PegIntron™/REBETOL combination therapy?

Possible, serious side effects include:

Mental health problems including suicide, blood problems, heart problems, body organ problems. See “What is the most important information I should know about PegIntron™ and PegIntron™/REBETOL combination therapy?”

Other body organ problems. A few patients have lung problems (such as pneumonia or inflammation of the lung tissue), inflammation of the kidney, and eye disorders.

New or worsening autoimmune disease. Some patients taking PegIntron™ or PegIntron™/REBETOL develop autoimmune diseases (a condition where the body’s immune cells attack other cells or organs in the body), including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. In some patients who already have an autoimmune disease, the disease worsens on PegIntron™ and PegIntron™/REBETOL combination therapy.

Common but less serious side effects include:

Flu-like symptoms. Most patients who take PegIntron™ or PegIntron™/REBETOL therapy have "flu-like" symptoms (headache, muscle aches, tiredness, and fever). Some of these symptoms (fever, headache) usually lessen after the first few weeks of therapy. You can reduce some of these symptoms by injecting your PegIntron™ dose at bedtime. Over-the-counter pain and fever reducers, such as acetaminophen or ibuprofen, can be used to prevent or reduce the fever and headache.
Extreme fatigue (tiredness). Many patients become extremely tired while on PegIntron™ or PegIntron™/REBETOL combination therapy.

Appetite problems. Nausea, loss of appetite, and weight loss, occur commonly.

Thyroid problems. Some patients develop changes in the function of their thyroid. Symptoms of thyroid changes include the inability to concentrate, feeling cold or hot all the time, a change in your weight, and changes to your skin.

Blood sugar problems. Some patients develop problems with the way their body controls their blood sugar, and may develop high blood sugar or diabetes.

Skin reactions. Redness, swelling, and itching are common at the site of injection. If after several days these symptoms do not disappear contact your health care provider. You may get a rash during therapy. If this occurs, your health care provider may recommend medicine to treat the rash.

Hair thinning. Hair thinning is common during PegIntron™ and PegIntron™/REBETOL treatment. Hair loss stops and hair growth returns after therapy is stopped.

These are not all of the side effects of PegIntron™ or PegIntron™/REBETOL combination therapy. Your health care provider or pharmacist can give you a more complete list.

General advice about prescription medicines:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any concerns about PegIntron™, ask your health care provider. Your health care provider or pharmacist can give you information about PegIntron™ that was written for health care professionals. Do not use PegIntron™ for a condition for which it was not prescribed. Do not share this medication with other people.

If you are taking PegIntron™/REBETOL combination therapy, also read the Medication Guide for REBETOL (ribavirin, USP) Capsules.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by: Schering Corporation, Kenilworth, NJ 07033 USA

DATE

How do I prepare and inject the PegIntron™ Dose?
Before you inject PegIntron™, the powder must be mixed with 0.7 mL of the supplied DILUENT for PegIntron™, Sterile Water for Injection (diluent). You should carefully follow the directions given to you by your health care provider.

The vial of mixed PegIntron™ should be used immediately. DO NOT prepare more than one vial at a time. If you don’t use the vial of the prepared solution right away, it must be stored in a refrigerator and used within 24 hours.
Storing PegIntron™

PegIntron™ Powder should be stored at room temperature (25 °C, 77°F); avoid exposure to heat. After mixing, the PegIntron™ solution should be used immediately but may be stored in the refrigerator up to 24 hours. The solution contains no preservatives. DO NOT FREEZE.

Preparing the PegIntron™ solution

1. Find a clean, well-lit, non-slip flat working surface and assemble all of the supplies you will need for an injection. All of the supplies you will need for an injection are in the PegIntron™ Powder for Injection package. The package contains:
   - a vial of PegIntron™ powder
   - a 1.25 mL vial of DILUENT
   - 2 disposable syringes, and
   - alcohol swabs

2. Check the date printed on the PegIntron™ carton to make sure that the expiration date has not passed. Remove one vial and look at the contents. The PegIntron™ in the vial should appear as a white to off-white tablet-like solid, that is whole/in pieces or as a loose powder.

   If you have already mixed the PegIntron™ solution and it has been stored properly in the refrigerator, take it out of the refrigerator and allow the solution to come to room temperature.

3. Wash your hands thoroughly with soap and water, rinse and towel dry. It is important to keep your work area, your hands, and injection site clean to minimize the risk of infection.

   The disposable syringes have needles that are already attached and cannot be removed. Each syringe has a clear plastic safety sleeve that is pulled over the needle for disposal after use. The safety sleeve should remain tight against the flange while using the syringe and moved over the needle only when ready for disposal (Figure A).

   The syringes and needles are for single use only.
4. Remove the protective wrapper from ONE of the syringes provided and use for the following steps 5-7. Make sure that the syringe safety sleeve is sitting against the flange (Figure A).

5. Remove the protective plastic cap from the tops of both the supplied DILUENT and the PegIntron™ vials. Clean the rubber stopper on the top of both vials with an alcohol swab.

6. Carefully remove the protective cap straight off of the needle to avoid damaging the needle point. Fill the syringe with air by pulling the plunger to 0.7 mL (Figure B). Hold the DILUENT vial upright. Do not touch the cleaned top of the vial with your hands (Figure C). Insert the needle through the center of the rubber stopper of the DILUENT vial, and inject the air from the syringe into the vial (Figure D). Turn the vial upside down and make sure the tip of the needle is in the liquid. **Withdraw only 0.7 mL of DILUENT** by pulling the plunger back to 0.7 mL mark on the side of the syringe (Figure E). Remove the needle from the vial (Figure F). **Discard the remaining DILUENT.**
7. Insert the needle through the center of the rubber stopper of the PegIntron™ vial, and place the needle tip against the glass wall of the vial (Figure G). SLOWLY inject the 0.7 mL DILUENT so that the stream of DILUENT runs down the side of the vial. To prevent bubbles from forming, DO NOT AIM THE STREAM of diluent directly on the tablet-like SOLID or POWDER in the bottom of the vial. Remove the needle from the vial. Firmly grasp the safety sleeve and pull it over the exposed needle until you hear a click. The green stripe on the safety sleeve will completely cover the red stripe on the needle. (See Figure O in the section: “Injecting the PegIntron™ dose.”) Discard the syringe and needle in the puncture proof container.

8. GENTLY swirl the vial in a gentle circular motion (Figure H), until the PegIntron™ is completely dissolved. DO NOT SHAKE the vial. If any powder remains undissolved in the vial, gently turn the vial upside down until all of the powder is dissolved. It is not unusual for the solution to appear cloudy or bubbly for a few minutes. If air bubbles do form, wait until the solution has settled and all bubbles have risen to the top before withdrawing your dose from the vial.

9. After the solution has settled and is completely dissolved it should be clear, colorless, and without particles, but there may be a ring of foam or bubbles on the surface, this is normal. Do not use it if you see particles or the color is not correct.

10. After the PegIntron™ powder is dissolved but before you withdraw your dose, clean the rubber stopper again with an alcohol swab.
11. Unwrap the second syringe provided. You will use it to give yourself the injection. Carefully remove the protective cap from the needle and fill the syringe with air by pulling the plunger to the number on the side of the syringe (mL) that corresponds to your prescribed dose (Figure J). Hold the PegIntron™ vial upright. DO NOT touch the cleaned top of the vial with your hands (Figure K). Insert the needle into the vial containing the PegIntron™ solution and inject the air into the center of the vial (Figure L).

12. Turn the PegIntron™ vial upside down. Be sure the tip of needle is in the PegIntron™ solution. While holding the vial and syringe with one hand slowly pull the plunger back to withdraw the exact amount of PegIntron™ into the syringe your health care provider told you to use (Figure M).

13. Remove the needle from the vial (Figure N) and check for air bubbles in the syringe. If you see any bubbles, hold the syringe with the needle pointing up and gently tap the syringe gently until the bubbles rise. Then push the plunger in slowly until the bubbles disappear.
Injecting the PegIntron™ Dose

Selecting the Site for Injection.

The best sites for giving yourself an injection are those areas with a layer of fat between the skin and muscle, like your thigh, the outer surface of your upper arm, and abdomen. Do not inject yourself in the area near your navel or waistline. If you are very thin, you should only use the thigh or outer surface of the arm for injection.

You should use a different site each time you inject PegIntron™ to avoid soreness at any one site. Do not inject PegIntron™ solution into an area where the skin is irritated, red, bruised, infected or has scars, stretch marks, or lumps.

14. Clean the skin where the injection is to be given with an alcohol swab, and wait for the area to dry. Remove the protective cap from the needle. Make sure the safety sleeve of the syringe is pushed firmly against the syringe flange so that the needle is fully exposed (Figure A).

15. With one hand, pinch a 2-inch fold of loose skin. With your other hand, pick up the syringe and hold it like a pencil. Position the bevel of the needle facing up and insert the needle approximately ¼ inch into the pinched skin at approximately a 45- to 90-degree angle with a quick dart-like thrust. After the needle is in, remove the hand that you used to pinch your skin and use it to hold the syringe barrel. Pull the plunger of the syringe back very slightly. If blood comes into the syringe, the needle has entered a blood vessel. Do not inject. Withdraw the needle and discard the syringe as outlined in step 17. Repeat the above steps with a new vial to prepare a new syringe and inject the medicine at a new site. If no blood is present in the syringe, inject the medicine by gently pressing the plunger all the way down the syringe barrel.

16. Hold an alcohol swab near the needle and pull the needle straight out of the skin. Press the alcohol swab over the injection site for several seconds. Do not massage the injection site. If there is bleeding, cover it with a bandage.

17. After injecting your dose, firmly grasp the safety sleeve and pull it over the exposed needle until you hear a click, and the green stripe on the safety sleeve covers the red stripe on the needle (Figure O). Discard the syringe and needle in the Sharp’s container supplied to you.

Figure O
18. After 2 hours, check the injection site for redness, swelling, or tenderness. If you have a skin reaction and it doesn’t clear up in a few days, contact your health care provider or nurse.

**How do I dispose of the used syringes and needles?**
Discard used safety lock syringes and needles in a Sharp’s container or other puncture-proof container like a coffee can. DO NOT USE glass or clear plastic containers. Your health care provider or nurse will tell you how to dispose of a full container. Always keep the container out of reach of children.

Manufactured by: Schering Corporation, Kenilworth, NJ 07033 USA

**DATE 12/06**
MEDICATION GUIDE

PegIntron™ Redipen® Single-dose Delivery System
Peginterferon alfa-2b

Including appendix with instructions for using PegIntron™ Redipen® Single-dose Delivery System

Read this Medication Guide carefully before you start taking PegIntron™ (Peg In-tron) or PegIntron™/REBETOL (REB-eh-tol) combination therapy. Read the Medication Guide each time you refill your prescription because there may be new information. The information in this Medication Guide does not take the place of talking with your health care provider (doctor, nurse, nurse practitioner, or physician’s assistant).

If you are taking PegIntron™/REBETOL combination therapy, also read the Medication Guide for REBETOL (ribavirin, USP) Capsules.

What is the most important information I should know about PegIntron™ and PegIntron™/REBETOL combination therapy?

PegIntron™ (peginterferon) is a treatment for some people who are infected with hepatitis C virus. However, PegIntron™ and PegIntron™/REBETOL combination therapy can have serious side effects that may cause death in rare cases. Before you decide to start treatment, you should talk to your health care provider about the possible benefits and side effects of PegIntron™ or PegIntron™/REBETOL combination therapy. If you begin treatment you will need to see your health care provider regularly for medical examinations and lab tests to make sure your treatment is working and to check for side effects.

REBETOL capsules may cause birth defects and/or death of an unborn child. If you are pregnant, you or your male partner must not take PegIntron™/REBETOL combination therapy. You must not become pregnant while either you or your partner are being treated with the combination PegIntron™/REBETOL therapy, or for 6 months after stopping therapy. Men and women should use birth control while taking the combination therapy and for 6 months afterwards. If you or your partner are being treated and you become pregnant, either during treatment or within 6 months of stopping treatment, call your health care provider right away. There is a Ribavirin Pregnancy Registry that collects information about pregnancy outcomes in female patients and female partners of male patients exposed to ribavirin. You or your health care provider are encouraged to contact the Registry at 1-800-593-2214.

If you are taking PegIntron™ or PegIntron™/REBETOL therapy you should call your health care provider immediately if you develop any of these symptoms:

New or worsening mental health problems, such as thoughts about killing or hurting yourself or others, trouble breathing, chest pain, severe stomach or lower back pain,
bloody diarrhea or bloody bowel movements, high fever, bruising, bleeding, or decreased vision.

The most serious possible side effects of PegIntron™ and PegIntron™/REBETOL therapy include:

Problems with Pregnancy. Combination PegIntron™/REBETOL therapy can cause death, serious birth defects, or other harm to your unborn child. If you are a woman of childbearing age, you must not become pregnant during treatment and for 6 months after you have stopped therapy. You must have a negative pregnancy test immediately before beginning treatment, during treatment, and for 6 months after you have stopped therapy. Both males and female patients must use effective forms of birth control during treatment and for the 6 months after treatment is completed. Male patients should use a condom. If you are a female, you must use birth control even if you believe that you are not fertile or that your fertility is low. You should talk to your health care provider about birth control for you and your partner.

Mental health problems and suicide. PegIntron™ and PegIntron™/REBETOL therapies may cause patients to develop mood or behavioral problems. These can include irritability (getting easily upset) and depression (feeling low, feeling bad about yourself, or feeling hopeless). Some patients may have aggressive behavior. Former drug addicts may fall back into drug addiction or overdose. Some patients think about hurting or killing themselves or other people and some have killed (suicide) or hurt themselves or others. You must tell your health care provider if you are being treated for a mental illness or had treatment in the past for any mental illness, including depression and suicidal behavior. You should tell your health care provider if you have ever been addicted to drugs or alcohol.

Heart problems. Some patients taking PegIntron™ or PegIntron™/REBETOL therapy may develop problems with their heart, including low blood pressure, fast heart rate, and very rarely, heart attacks. Tell your health care provider if you have had any heart problems in the past.

Blood problems. PegIntron™ and PegIntron™/REBETOL therapies commonly lower two types of blood cells (white blood cells and platelets). In some patients, these blood counts may fall to dangerously low levels. If your blood counts become very low, this could lead to infections or bleeding.

REBETOL therapy causes a decrease in the number of red blood cells you have (anemia). This can be dangerous, especially for patients who already have heart or circulatory (cardiovascular) problems. Talk with your health care provider before taking combination PegIntron™/REBETOL therapy if you have, or have ever had any cardiovascular problems.

Body organ problems. Certain symptoms like severe stomach pain may mean that your internal organs are being damaged.
For other possible side effects, see “What are the possible side effects of PegIntron™ and PegIntron™/REBETOL” in this Medication Guide.

What is PegIntron™ and PegIntron™/REBETOL combination therapy?
The PegIntron™ product is a drug used to treat adults who have a lasting (chronic) infection with hepatitis C virus and who show signs that the virus is damaging the liver.

PegIntron™/REBETOL combination therapy consists of two medications also used to treat hepatitis C infection. Patients with hepatitis C have the virus in their blood and in their liver. PegIntron™ reduces the amount of virus in the body and helps the body's immune system fight the virus. REBETOL (ribavirin) is a drug that helps to fight the viral infection, but does not work when used by itself to treat chronic hepatitis C.

It is not known if PegIntron™ or PegIntron™/REBETOL therapies can cure hepatitis C (permanently eliminate the virus), or if it can prevent liver failure or liver cancer that is caused by hepatitis C infection.

It is also not known if PegIntron™ or PegIntron™/REBETOL combination therapy will prevent one infected person from infecting another person with hepatitis C.

Who should not take PegIntron™ or PegIntron™/REBETOL therapy?
Do not take PegIntron™ or PegIntron™/REBETOL therapy if you:

- are pregnant, planning to get pregnant during treatment or during the 6 months after treatment, or breast-feeding
- are a male patient with a female sexual partner who is pregnant, or plans to become pregnant at any time while you are being treated with REBETOL, or during the 6 months after your treatment has ended.

- have hepatitis caused by your immune system attacking your liver (autoimmune hepatitis) or unstable liver disease

- had an allergic reaction to another alpha interferon or are allergic to any of the ingredients in PegIntron™ or REBETOL Capsules. If you have any doubts, ask your health care provider.

- Do not take PegIntron™/REBETOL combination therapy if you have abnormal red blood cells such as sickle-cell anemia or thalassemia major.

If you have any of the following conditions or serious medical problems, discuss them with your health care provider before taking PegIntron™ or PegIntron™/REBETOL therapy:

- depression or anxiety
- sleep problems
- high blood pressure
- previous heart attack, or other heart problems
• liver problems (other than hepatitis C infection)
• any kind of autoimmune disease (where the body’s immune system attacks the body’s own cells), such as psoriasis, systemic lupus erythematosus, rheumatoid arthritis
• thyroid problems
• diabetes
• colitis (inflammation of the bowels)
• cancer
• hepatitis B infection
• HIV infection
• kidney problems
• bleeding problems
• alcoholism
• drug abuse or addiction
• body organ transplant and are taking medicine that keeps your body from rejecting your transplant (suppresses your immune system).

How should I take PegIntron™ or PegIntron™/REBETOL?

Your health care provider will decide whether you will take PegIntron™ therapy alone or the combination of PegIntron™/REBETOL, as well as the correct dose (based on your weight). PegIntron™ and PegIntron™/REBETOL are given for one year. Take your prescribed dose of PegIntron™ ONCE A WEEK, on the same day of each week and at approximately the same time. Take the medicine for the full year and do not take more than the prescribed dose. REBETOL Capsules should be taken with food. When you take REBETOL with food, more of the medicine (70% more on average) is taken up by your body. You should take REBETOL the same way every day (twice a day with food) to keep the medicine in your body at a steady level. This will help your health care provider to decide how your treatment is working and how to change the number of REBETOL capsules you take if you have side effects from REBETOL. Be sure to read the Medication Guide for REBETOL (ribavirin, USP) for complete instructions on how to take the REBETOL capsules.

You should be completely comfortable with how to prepare PegIntron™; how to set the dose you take; and how to inject yourself before you use PegIntron™ for the first time. PegIntron™ comes in two different forms, a powder in a single-use vial and a Redipen® single-use delivery system. See the attached appendix for detailed instructions for preparing and giving a dose of PegIntron™.

If you miss a dose of the PegIntron™ product, take the missed dose as soon as possible during the same day or the next day, then continue on your regular dosing schedule. If several days go by after you miss a dose, check with your health care provider about what to do. Do not double the next dose or take more than one dose a week without talking to your health care provider. Call your health care provider right away if you take more than your prescribed PegIntron™ dose. Your health care provider may wish to examine you more closely, and take blood for testing.
If you miss a dose of REBETOL capsules, take the missed dose as soon as possible during the same day. If an entire day has gone by, check with your health care provider about what to do. Do not double the next dose.

You must get regular blood tests to help your health care provider check how the treatment is working and to check for side effects.

Tell your health care provider if you are taking or planning to take other prescription or non-prescription medicines, including vitamin and mineral supplements and herbal medicines.

**What should I avoid while taking PegIntron™ or PegIntron™/REBETOL therapies?**

- If you are pregnant do not start taking PegIntron™/REBETOL combination therapy.
- Avoid becoming pregnant while taking PegIntron™ or PegIntron™/REBETOL.
- PegIntron™ and PegIntron™/REBETOL may harm your unborn child (death or serious birth defects) or cause you to lose your baby (miscarry). **If you or your partner becomes pregnant during treatment or during the 6 months after treatment with PegIntron™/REBETOL combination therapy, immediately report the pregnancy to your health care provider. You or your health care provider should call 1-800-593-2214.** By calling this number, information about you and/or your partner will be added to a pregnancy registry that will be used to help you and your health care provider make decisions about your treatment for hepatitis in the future. You, your partner, and/or your health care provider will be asked to provide follow-up information on the outcome of the pregnancy.
- Do not breast-feed your baby while taking PegIntron™.

**What are the possible side effects of PegIntron™ and PegIntron™/REBETOL combination therapy?**

**Possible, serious side effects include:**

**Mental health problems including suicide, blood problems, heart problems, body organ problems.** See “What is the most important information I should know about PegIntron™ and PegIntron™/REBETOL combination therapy?”

**Other body organ problems.** A few patients have lung problems (such as pneumonia or inflammation of the lung tissue), inflammation of the kidney, and eye disorders.

**New or worsening autoimmune disease.** Some patients taking PegIntron™ or PegIntron™/REBETOL develop autoimmune diseases (a condition where the body’s immune cells attack other cells or organs in the body), including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. In some patients who already have an autoimmune disease, the disease worsens on PegIntron™ and PegIntron™/REBETOL combination therapy.

**Common but less serious side effects include:**
Flu-like symptoms. Most patients who take PegIntron™ or PegIntron™/REBETOL therapy have "flu-like" symptoms (headache, muscle aches, tiredness, and fever). Some of these symptoms (fever, headache) usually lessen after the first few weeks of therapy. You can reduce some of these symptoms by injecting your PegIntron™ dose at bedtime. Over-the-counter pain and fever reducers, such as acetaminophen or ibuprofen, can be used to prevent or reduce the fever and headache.

Extreme fatigue (tiredness). Many patients become extremely tired while on PegIntron™ or PegIntron™/REBETOL combination therapy.

Appetite problems. Nausea, loss of appetite, and weight loss, occur commonly.

Thyroid problems. Some patients develop changes in the function of their thyroid. Symptoms of thyroid changes include the inability to concentrate, feeling cold or hot all the time, a change in your weight, and changes to your skin.

Blood sugar problems. Some patients develop problems with the way their body controls their blood sugar and may develop high blood sugar or diabetes.

Skin reactions. Redness, swelling, and itching are common at the site of injection. If after several days these symptoms do not disappear contact your health care provider. You may get a rash during therapy. If this occurs, your health care provider may recommend medicine to treat the rash.

Hair thinning. Hair thinning is common during PegIntron™ and PegIntron™/REBETOL treatment. Hair loss stops and hair growth returns after therapy is stopped.

These are not all of the side effects of PegIntron™ or PegIntron™/REBETOL combination therapy. Your health care provider or pharmacist can give you a more complete list.

General advice about prescription medicines:
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you have any concerns about PegIntron™, ask your health care provider. Your health care provider or pharmacist can give you information about PegIntron™ that was written for health care professionals. Do not use PegIntron™ for a condition for which it was not prescribed. Do not share this medication with other people.

If you are taking PegIntron™/REBETOL combination therapy, also read the Medication Guide for REBETOL (ribavirin, USP) Capsules.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

How do I prepare and inject the PegIntron™ Redipen® Dose?
The PegIntron™ Redipen® system is for a single use, by one person only. The Redipen® must not be shared. Use only the injection needle provided in the packaging for the
PegIntron™ Redipen® system. If you have problems with the Redipen® system or the PegIntron™ solution, you should contact your health care provider or pharmacist.

The following instructions explain how to prepare and inject yourself with the PegIntron™ Redipen® system. Please read the instructions carefully and follow them step by step. Your health care provider will instruct you on how to self-inject with the PegIntron™ Redipen®. Do not attempt to inject yourself unless you are sure you understand the procedure and requirements for self-injection.

How to use the PegIntron™ Redipen® single-dose delivery system.

Storing PegIntron™

PegIntron™ Redipen® should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F); avoid exposure to heat. After mixing, the PegIntron™ solution should be used immediately but may be stored in the refrigerator up to 24 hours at 2°C to 8°C (36°F to 46°F). The solution contains no preservatives. DO NOT FREEZE.

Preparation

1. Find a clean, well-lit, non-slip flat working surface and assemble all of the supplies you will need for an injection. All of the supplies you will need are in the PegIntron™ Redipen® package. The package contains:
   - a PegIntron™ Redipen® single-dose delivery system
   - one disposable needle
   - two alcohol swabs, and
   - dosing tray; (The dosing tray is the bottom half of the Redipen® package.)

2. Take the PegIntron™ Redipen® out of the refrigerator and allow the medicine to come to room temperature. Before removing the Redipen® from the carton, check the expiration date printed on the PegIntron™ Redipen® carton to make sure that the expiration date has not passed. Do not use if the expiration date has passed.

3. After taking the PegIntron™ Redipen® out of the carton, look in the window of the Redipen® and make sure the PegIntron™ in the cartridge holder window is a white, to off-white tablet that is whole, or in pieces, or powdered.

4. Wash your hands thoroughly with soap and water, rinse, and towel dry. It is important to keep your work area, your hands, and the injection site clean to minimize the risk of infection.

1. Mix the Drug
Key points:

Before you mix the PegIntron™, make sure it is at room temperature. It is important that you keep the PegIntron™ Redipen® UPRIGHT (Dosing Button down) as shown in Figure 1.

a. Hold the PegIntron™ Redipen® UPRIGHT (Figure 1a) in the dosing tray on a hard, flat, non-slip surface with the dosing button down. You may want to hold the Redipen® using the grip.

b. To mix the powder and the liquid, keep the Redipen® upright in the dosing tray and press the top half of the Redipen® downward toward the hard, flat, non-slip surface until you hear the click (Figure 1b). Once you’ve heard the click, you will notice in the window that both dark stoppers are now touching. The dosing button should be flush with the pen body.

c. Wait several seconds for the powder to completely dissolve.

d. Gently turn the PegIntron™ Redipen® upside down twice (Figure 2). To avoid excessive foaming, DO NOT SHAKE.
e. Keeping the PegIntron™ Redipen® **UPRIGHT**, with the dosing button down, check through the Redipen® window to see if the mixed PegIntron™ solution is completely dissolved. The solution should be clear, colorless, and without particles **before use**. It is normal to see some small bubbles near the top of the solution. Do not use if the solution is not clear, or if you see particles.

f. **Place the PegIntron™ Redipen®** back into the dosing tray provided in the packaging (Figure 3). The dosing button will be on the bottom.

2. **Attach the Needle**

  a. Wipe the rubber membrane of the PegIntron™ Redipen® with one alcohol swab.
  b. Remove the protective paper tab from the injection needle, but do NOT remove either the outer cap or the yellow inner cap from the injection needle. Keeping the PegIntron™ Redipen® UPRIGHT in the dosing tray, FIRMLY push the injection needle straight into the Redipen® rubber membrane, and screw it firmly in place, in a clockwise direction (Figure 4). Remember
to leave the needle caps in place when you attach the needle to the Redipen®. Pushing the needle through the rubber membrane, “primes” the needle and allows the extra liquid and air in the pen to be removed.

NOTE: Some fluid will trickle out. This is normal. The dark stoppers move up and you will no longer see the fluid in the window once the needle is successfully primed.

c. IMPORTANT: Keep the Redipen® in the UPRIGHT position and keep the outer needle cap on until you are ready to inject.

3. Dialing the Dose

a. Remove the PegIntron™ Redipen® from the dosing tray (Figure 5a).

Holding the PegIntron™ Redipen® firmly, pull the dosing button out as far as it will go. You will see a dark band:

Do not push the dosing button in until you are ready to self-inject the PegIntron™ dose.
b. Turn the dosing button until your prescribed dose is lined up with the dosing tab (Figure 5b). The dosing button will turn freely. If you have trouble dialing your dose, check to make sure the dosing button has been pulled out as far as it will go (Figure 5c).

c. Carefully lay the PegIntron™ Redipen® down on a hard, flat, non-slip surface. Do NOT remove either of the needle caps and do NOT push the dosing button in until you are ready to self-inject the PegIntron™ dose.

4. Injecting the PegIntron™ Dose

Choosing an Injection Site

The best sites for giving yourself an injection are those areas with a layer of fat between the skin and muscle, like your thigh, the outer surface of your upper arm, and abdomen. Do not inject yourself in the area near your navel or waistline. If you are very thin, you should only use the thigh or outer surface of the arm for injection.
You should use a different site each time you inject PegIntron™ to avoid soreness at any one site. Do not inject PegIntron™ into an area where the skin is irritated, red, bruised, infected, or has scars, stretch marks, or lumps.

- Clean the skin where the injection is to be given with the second alcohol swab provided, and wait for the area to dry.
- Remove the outer cap from the needle (Figure 6a). There may be some liquid around the yellow inner needle cap (Figure 6b). This is normal.
- Once the injection site is dry, remove the yellow inner needle cap (Figure 6c). You are now ready to inject.

- Hold the PegIntron™ Redipen® with your fingers wrapped around the pen body barrel and your thumb on the dosing button (Figure 7).
  - With your other hand, pinch the skin in the area you have cleaned for injection.
  - Insert the needle into the pinched skin at an angle of 45° to 90°.
  - Press the dosing button down slowly and firmly until you can’t push it any further.
• Keep your thumb pressed down on the dosing button for an additional 5 seconds to ensure that you get the complete dose.

• Remove the needle from your skin.

Figure 7

e. Gently press the injection site with a small bandage or sterile gauze if necessary for a few seconds but do not massage the injection site. If there is bleeding, cover with an adhesive bandage. **DO NOT RECAP THE NEEDLE and DO NOT REUSE the Redipen®.**

**How do I Dispose of the Redipen®?**
Discard the Redipen® and needle and any solution remaining in the Redipen® in a sharps container or other puncture-resistant container like a metal coffee can. **DO NOT use glass or clear plastic containers.** Ask your health care provider how to dispose of a full container. Always keep the container out of reach of children.

**After 2 hours, check the injection site for redness, swelling, or tenderness.**
**If you have a skin reaction and it doesn’t clear up in a few days, contact your health care provider.**

Manufactured by: Schering Corporation, Kenilworth, NJ 07033 USA
DATE 12/06